Evidence map›Paper›PMID 38892097›Full record

ArticleInternational journal of molecular sciences2024

Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast Cancer.

Léa Louise Volmer, Dominik Dannehl, Sabine Matovina, Florin-Andrei Taran, Christina Barbara Walter, Markus Wallwiener, Sara Yvonne Brucker, Andreas Daniel Hartkopf, Tobias Engler

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Léa Louise VolmerDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.
Dominik DannehlDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.ORCID 0000-0002-7653-8283
Sabine MatovinaDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.
Florin-Andrei TaranDepartment for Gynecology and Obstetrics, Freiburg University, 79085 Freiburg im Breisgau, Germany.ORCID 0000-0001-7384-2928
Christina Barbara WalterDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.ORCID 0000-0002-3059-7595
Markus WallwienerDepartment for Gynecology and Obstetrics, University Medical Center Halle, 06120 Halle (Saale), Germany.
Sara Yvonne BruckerDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.ORCID 0000-0001-8588-1094
Andreas Daniel HartkopfDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.ORCID 0000-0003-1227-1118
Tobias EnglerDepartment of Women's Health, Tübingen University, 72076 Tübingen, Germany.ORCID 0000-0002-8063-2053

Funding

This study was financially supported by the German Cancer Aid (Priority Program 'Translational Oncology: DETECT-CTC-HIGH'; Project-ID: 70114705).The work described in this paper was conducted in the framework of the Graduate School 2543/1 "Intraoperative This study was financially supported by the German Cancer Aid (Priority Program 'Translational Oncology: DETECT-CTC-HIGH'; Project-ID: 70114705).The work described in this paper was conducted in the framework of the Graduate School 2543/1 "Intraoperative
6 · The paper itself

Abstract

Breast cancer remains a leading cause of cancer mortality in women globally. Despite advancements in systemic therapy, the risk of distant recurrence persists even after such treatment and may be linked to disseminated tumor cells (DTCs). Variability in molecular characteristics between primary tumors (PTs) and distant metastases underscores the need to comprehensively understand metastatic pathways. This retrospective study investigated discrepancies between HER2 expression in PTs and DTCs and their implications for survival outcomes in 201 early breast cancer (EBC) patients. We found a significant association between HER2 expression in PTs and DTCs when classifying tumors as HER2-high/low/negative. Patients whose HER2 status was discordant between PTs and DTCs exhibited worse distant disease-free survival than those with concordant status. Multivariate analysis confirmed the HER2 status of DTCs as an independent prognostic factor for distant DFS. These findings emphasize the importance of assessing HER2 expression in DTCs and its potential implications for tailored therapy strategies in EBC. Furthermore, prospective trials are needed to validate these findings and explore targeted therapies based on the molecular characteristics of DTCs.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedBiomarkers, TumorDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesbreast cancerdisseminated tumor cellsminimal residual diseasetargeted therapy

Identifiers

PMID38892097
PMCPMC11173203

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.